Epigenetic modification of ferroptosis by non-coding RNAs in cancer drug resistance

The development of drug resistance remains a major challenge in cancer treatment. Ferroptosis, a unique type of regulated cell death, plays a pivotal role in inhibiting tumour growth, presenting new opportunities in treating chemotherapeutic resistance. Accumulating studies indicate that epigenetic...

Full description

Saved in:
Bibliographic Details
Published inMolecular cancer Vol. 23; no. 1; pp. 177 - 22
Main Authors Wang, Hongquan, Fleishman, Joshua S., Cheng, Sihang, Wang, Weixue, Wu, Fan, Wang, Yumin, Wang, Yu
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 27.08.2024
BioMed Central
BMC
Subjects
Animals
Antineoplastic Agents - pharmacology
Antineoplastic Agents - therapeutic use
Cancer
Cell death
Chemotherapy
Development and progression
Drug resistance
Drug Resistance, Neoplasm - genetics
Drug therapy
Epigenesis, Genetic
Epigenetic inheritance
Ferroptosis
Ferroptosis - drug effects
Ferroptosis - genetics
Gene Expression Regulation, Neoplastic - drug effects
Humans
Neoplasms - drug therapy
Neoplasms - genetics
Neoplasms - metabolism
Neoplasms - pathology
Non-coding RNAs
Review
RNA, Untranslated - genetics
Non-coding RNAs
Ferroptosis
Drug resistance
Cancer
Online AccessGet full text

Cover

Abstract The development of drug resistance remains a major challenge in cancer treatment. Ferroptosis, a unique type of regulated cell death, plays a pivotal role in inhibiting tumour growth, presenting new opportunities in treating chemotherapeutic resistance. Accumulating studies indicate that epigenetic modifications by non-coding RNAs (ncRNA) can determine cancer cell vulnerability to ferroptosis. In this review, we first summarize the role of chemotherapeutic resistance in cancer growth/development. Then, we summarize the core molecular mechanisms of ferroptosis, its upstream epigenetic regulation, and its downstream effects on chemotherapeutic resistance. Finally, we review recent advances in understanding how ncRNAs regulate ferroptosis and from such modulate chemotherapeutic resistance. This review aims to enhance general understanding of the ncRNA-mediated epigenetic regulatory mechanisms which modulate ferroptosis, highlighting the ncRNA-ferroptosis axis as a key druggable target in overcoming chemotherapeutic resistance.
AbstractList Abstract The development of drug resistance remains a major challenge in cancer treatment. Ferroptosis, a unique type of regulated cell death, plays a pivotal role in inhibiting tumour growth, presenting new opportunities in treating chemotherapeutic resistance. Accumulating studies indicate that epigenetic modifications by non-coding RNAs (ncRNA) can determine cancer cell vulnerability to ferroptosis. In this review, we first summarize the role of chemotherapeutic resistance in cancer growth/development. Then, we summarize the core molecular mechanisms of ferroptosis, its upstream epigenetic regulation, and its downstream effects on chemotherapeutic resistance. Finally, we review recent advances in understanding how ncRNAs regulate ferroptosis and from such modulate chemotherapeutic resistance. This review aims to enhance general understanding of the ncRNA-mediated epigenetic regulatory mechanisms which modulate ferroptosis, highlighting the ncRNA-ferroptosis axis as a key druggable target in overcoming chemotherapeutic resistance.
The development of drug resistance remains a major challenge in cancer treatment. Ferroptosis, a unique type of regulated cell death, plays a pivotal role in inhibiting tumour growth, presenting new opportunities in treating chemotherapeutic resistance. Accumulating studies indicate that epigenetic modifications by non-coding RNAs (ncRNA) can determine cancer cell vulnerability to ferroptosis. In this review, we first summarize the role of chemotherapeutic resistance in cancer growth/development. Then, we summarize the core molecular mechanisms of ferroptosis, its upstream epigenetic regulation, and its downstream effects on chemotherapeutic resistance. Finally, we review recent advances in understanding how ncRNAs regulate ferroptosis and from such modulate chemotherapeutic resistance. This review aims to enhance general understanding of the ncRNA-mediated epigenetic regulatory mechanisms which modulate ferroptosis, highlighting the ncRNA-ferroptosis axis as a key druggable target in overcoming chemotherapeutic resistance.
The development of drug resistance remains a major challenge in cancer treatment. Ferroptosis, a unique type of regulated cell death, plays a pivotal role in inhibiting tumour growth, presenting new opportunities in treating chemotherapeutic resistance. Accumulating studies indicate that epigenetic modifications by non-coding RNAs (ncRNA) can determine cancer cell vulnerability to ferroptosis. In this review, we first summarize the role of chemotherapeutic resistance in cancer growth/development. Then, we summarize the core molecular mechanisms of ferroptosis, its upstream epigenetic regulation, and its downstream effects on chemotherapeutic resistance. Finally, we review recent advances in understanding how ncRNAs regulate ferroptosis and from such modulate chemotherapeutic resistance. This review aims to enhance general understanding of the ncRNA-mediated epigenetic regulatory mechanisms which modulate ferroptosis, highlighting the ncRNA-ferroptosis axis as a key druggable target in overcoming chemotherapeutic resistance. Keywords: Cancer, Ferroptosis, Drug resistance, Non-coding RNAs
The development of drug resistance remains a major challenge in cancer treatment. Ferroptosis, a unique type of regulated cell death, plays a pivotal role in inhibiting tumour growth, presenting new opportunities in treating chemotherapeutic resistance. Accumulating studies indicate that epigenetic modifications by non-coding RNAs (ncRNA) can determine cancer cell vulnerability to ferroptosis. In this review, we first summarize the role of chemotherapeutic resistance in cancer growth/development. Then, we summarize the core molecular mechanisms of ferroptosis, its upstream epigenetic regulation, and its downstream effects on chemotherapeutic resistance. Finally, we review recent advances in understanding how ncRNAs regulate ferroptosis and from such modulate chemotherapeutic resistance. This review aims to enhance general understanding of the ncRNA-mediated epigenetic regulatory mechanisms which modulate ferroptosis, highlighting the ncRNA-ferroptosis axis as a key druggable target in overcoming chemotherapeutic resistance.The development of drug resistance remains a major challenge in cancer treatment. Ferroptosis, a unique type of regulated cell death, plays a pivotal role in inhibiting tumour growth, presenting new opportunities in treating chemotherapeutic resistance. Accumulating studies indicate that epigenetic modifications by non-coding RNAs (ncRNA) can determine cancer cell vulnerability to ferroptosis. In this review, we first summarize the role of chemotherapeutic resistance in cancer growth/development. Then, we summarize the core molecular mechanisms of ferroptosis, its upstream epigenetic regulation, and its downstream effects on chemotherapeutic resistance. Finally, we review recent advances in understanding how ncRNAs regulate ferroptosis and from such modulate chemotherapeutic resistance. This review aims to enhance general understanding of the ncRNA-mediated epigenetic regulatory mechanisms which modulate ferroptosis, highlighting the ncRNA-ferroptosis axis as a key druggable target in overcoming chemotherapeutic resistance.
ArticleNumber 177
Audience Academic
Author Wang, Hongquan
Wu, Fan
Wang, Yu
Cheng, Sihang
Wang, Yumin
Wang, Weixue
Fleishman, Joshua S.
Author_xml – sequence: 1
  givenname: Hongquan
  surname: Wang
  fullname: Wang, Hongquan
– sequence: 2
  givenname: Joshua S.
  surname: Fleishman
  fullname: Fleishman, Joshua S.
– sequence: 3
  givenname: Sihang
  surname: Cheng
  fullname: Cheng, Sihang
– sequence: 4
  givenname: Weixue
  surname: Wang
  fullname: Wang, Weixue
– sequence: 5
  givenname: Fan
  surname: Wu
  fullname: Wu, Fan
– sequence: 6
  givenname: Yumin
  surname: Wang
  fullname: Wang, Yumin
– sequence: 7
  givenname: Yu
  surname: Wang
  fullname: Wang, Yu
BackLink https://www.ncbi.nlm.nih.gov/pubmed/39192329$$D View this record in MEDLINE/PubMed
BookMark eNp9kt1r1TAYh4NsuA_9B7yQgDfedEuatEmv5DCmDobC9D7k423NaJNj0iPsvzc93WRHREppePO8T_PxO0NHIQZA6A0lF5TK9jLTuuOsIjUvL5GyEi_QKeWirXjTyaNn4xN0lvM9IVRIwV-iE9bRrmZ1d4q-XW_9AAFmb_EUne-91bOPAcce95BS3M4x-4zNAy5_r2xBwoDvvmwy9gFbHSwk7NJuwAkKNy-FV-i412OG14_fc3T38fr71efq9uunm6vNbWUb1s6VBUk6VnPKJC8DQ4mundHWGNdKTQ2lgljtjHDApaWOUAaUCEsYdY6do5tV6qK-V9vkJ50eVNRe7QsxDUqnsqsRlIEWOOHC1IZzWdOuAW5Fw1tpe01sXVwfVtd2ZyZwFsKc9HggPZwJ_oca4i9FKeOykYvh_aMhxZ87yLOafLYwjjpA3GXFSCdkU46_Kei7FR10WZsPfSxKu-BqI4lkopVCFOriH1R5HEzelhz0vtQPGt4-38OfxT9ddQHkCtgUc07QK-vn_V0Xsx8VJWpJlVpTpUqq1D5VanHXf7U-2f_T9BuRos5v
CitedBy_id crossref_primary_10_3389_fmed_2024_1527600
crossref_primary_10_1038_s41420_025_02290_6
crossref_primary_10_20517_cdr_2024_127
crossref_primary_10_1016_j_biopha_2024_117769
crossref_primary_10_3389_fimmu_2025_1518144
crossref_primary_10_3390_ijms252413334
crossref_primary_10_1097_JS9_0000000000002195
crossref_primary_10_3389_fphar_2024_1458412
crossref_primary_10_1016_j_ijbiomac_2025_142401
crossref_primary_10_1016_j_jep_2024_118936
crossref_primary_10_1016_j_mcp_2025_102013
crossref_primary_10_3892_ijo_2024_5714
crossref_primary_10_1016_j_bbcan_2024_189234
crossref_primary_10_1016_j_mtbio_2025_101696
crossref_primary_10_1016_j_prp_2025_155907
Cites_doi 10.1038/s41422-019-0263-3
10.1038/nrc3599
10.1073/pnas.75.1.280
10.1016/j.tcb.2023.04.005
10.3389/fmolb.2021.691795
10.1038/s41392-023-01341-7
10.1016/j.leukres.2014.12.008
10.1038/s41586-023-06983-9
10.1016/j.freeradbiomed.2018.09.014
10.1038/nrclinonc.2017.166
10.1016/j.cell.2017.11.048
10.1016/j.cell.2017.09.021
10.1016/j.drup.2021.100795
10.1186/s12943-020-01168-8
10.1016/j.biopha.2019.109233
10.1016/j.cell.2022.06.003
10.1016/j.drup.2010.02.001
10.1016/j.molcel.2020.11.024
10.3390/ijms21093233
10.1016/j.cell.2017.01.017
10.1038/s41586-021-03539-7
10.1038/s41420-020-00306-x
10.1038/s41556-024-01360-8
10.1083/jcb.202105043
10.1016/j.critrevonc.2022.103680
10.1016/j.jprot.2022.104777
10.1038/s41573-020-0077-5
10.2147/PGPM.S426205
10.1038/nchembio.2239
10.1038/s41418-020-00691-x
10.1038/s41420-024-01866-y
10.1016/j.tibs.2020.05.009
10.1111/cas.14578
10.1016/0092-8674(92)90519-I
10.1080/15548627.2020.1810918
10.2174/0929867328666210810115812
10.1038/s41556-019-0305-6
10.1038/s41419-024-06698-3
10.1016/j.cmet.2019.03.009
10.1007/s13238-021-00841-y
10.1016/j.drup.2021.100789
10.1016/j.bbrc.2020.01.066
10.1007/s10495-024-01948-3
10.1093/jnci/92.1.18
10.1089/ars.2021.0218
10.1038/s41580-018-0029-7
10.1016/j.ejmech.2022.114861
10.1016/j.cell.2013.12.010
10.1038/ncb3064
10.1021/acsnano.3c01199
10.1038/nrd.2016.117
10.1016/j.critrevonc.2020.103095
10.1038/s41392-022-01300-8
10.3390/ijms25073630
10.1186/s12967-023-04370-6
10.1038/s41598-019-46132-9
10.1038/nrd.2016.246
10.1038/s41418-022-00998-x
10.1038/s41420-020-0286-z
10.1002/ctm2.1300
10.1042/BSR20211812
10.1038/s41419-022-04927-1
10.1002/pmic.201800311
10.1016/j.cell.2012.03.042
10.1155/2014/360438
10.1038/s41392-023-01720-0
10.1007/s12272-019-01126-z
10.1016/j.cell.2023.05.003
10.1039/D1CS00265A
10.1016/j.drup.2022.100822
10.1021/acscentsci.9b01063
10.1038/sj.onc.1206951
10.1038/s41420-021-00709-4
10.1016/j.drup.2021.100796
10.1021/acschembio.5b00245
10.1002/tox.23509
10.1002/hep.28251
10.1016/j.tcb.2023.05.003
10.1177/09603271221142818
10.1016/j.celrep.2017.02.054
10.1007/s00439-014-1434-4
10.1007/s43440-020-00138-7
10.1016/j.ymthe.2021.03.022
10.1038/s41589-020-0472-6
10.1038/s41392-022-00975-3
10.1038/s41417-022-00581-z
10.1016/j.molcel.2018.10.042
10.1111/cge.13800
10.1038/s41586-019-1730-1
10.3892/or.2020.7836
10.1073/pnas.1603244113
10.1136/jitc-2021-004381
10.1038/s41571-022-00689-z
10.1007/s40618-023-02010-w
10.1158/0008-5472.CAN-06-0800
10.1021/acscentsci.7b00589
10.1074/jbc.274.17.11455
10.1038/s41589-020-0613-y
10.1038/s41586-019-1705-2
10.1186/s13045-022-01235-1
10.4161/rna.20481
10.1038/s41594-018-0054-4
10.1016/j.cell.2020.04.039
10.1016/j.brainresbull.2022.04.005
10.1016/j.ejca.2010.11.005
10.1186/s12943-023-01810-1
10.1038/s41467-021-22024-3
10.4143/crt.2016.572
10.1038/s41392-019-0095-0
10.1186/s13046-021-02208-x
10.3390/ijms22126587
10.1016/j.scib.2021.01.027
10.1186/s12943-022-01530-y
10.1016/j.drup.2019.07.003
10.1038/s41576-020-0270-8
10.2165/00129785-200505040-00003
10.1038/nchembio.2238
10.1038/s41586-023-06255-6
10.3389/fphar.2023.1207496
10.1038/s41420-021-00483-3
10.3389/fonc.2022.939605
10.1038/sj.onc.1207558
10.1016/j.ccell.2019.04.002
10.3390/cancers16040766
10.1038/nature16064
10.1089/ars.2019.7905
10.1016/j.ejmech.2023.115438
10.1080/15384047.2023.2223377
10.1016/j.phrs.2023.106739
10.1016/j.drup.2020.100683
10.1002/path.1706
10.1158/0008-5472.CAN-12-2217
10.1016/j.ccell.2016.03.010
10.1089/ars.2007.9.49
10.1073/pnas.75.1.285
10.3390/cancers13133210
10.1016/j.semcancer.2020.12.019
10.1002/mco2.267
10.1038/s41580-024-00703-5
10.1002/iub.1616
10.1016/0005-2760(82)90150-3
10.1002/jcp.31093
10.1016/j.biopha.2023.116074
10.1038/s41589-019-0408-1
10.3389/fnagi.2022.904152
10.1016/j.drup.2023.100936
10.1007/s13577-022-00699-0
10.1016/j.jprot.2023.105055
10.1038/s41586-019-1170-y
10.1038/s41591-019-0376-8
10.1016/j.molcel.2022.03.022
10.2174/0929867329666220629154418
10.1016/j.redox.2020.101744
10.2174/1566523216666160524144159
10.1038/s41568-022-00459-0
10.1016/j.drup.2021.100797
10.3389/fimmu.2022.847728
10.1038/s41598-019-53174-6
10.1016/j.drup.2019.100645
10.1038/s41573-021-00219-z
10.3389/fcell.2022.875318
10.3389/fphar.2022.909821
10.1186/s12964-023-01302-1
10.1146/annurev.biochem.71.102301.093055
10.3390/cancers15164187
10.1038/onc.2014.314
10.7150/ijbs.66917
10.1038/s41568-019-0149-1
10.1038/nature03098
10.1016/j.ejmech.2022.115015
10.1038/s41586-023-06878-9
10.1038/s41388-024-03057-6
10.1084/jem.20210518
10.1016/j.smim.2022.101606
10.1016/j.celrep.2019.07.107
10.1038/s41392-020-00300-w
10.1038/nrc3368
10.1016/j.trecan.2020.02.003
10.1016/0092-8674(92)90520-M
10.1038/s41568-020-00302-4
10.1080/10715762.2021.2024816
10.1016/j.canlet.2020.11.013
10.1038/s41420-024-01892-w
10.1007/s11427-020-1700-9
10.1038/sj.cgt.7700706
10.1038/s41586-019-1707-0
10.1016/j.bbagen.2012.11.020
10.3389/fonc.2021.780938
10.1158/2159-8290.CD-21-1059
10.1016/j.bbrc.2021.02.077
10.1021/acschembio.8b00199
10.1016/j.drup.2023.100960
10.1038/s41586-019-1411-0
10.1016/j.omtn.2022.03.020
10.1038/s41420-024-02035-x
10.3389/fcell.2020.590226
10.3389/fonc.2022.862015
10.1038/s41580-020-00324-8
10.1155/2022/2843990
10.1016/j.molmed.2015.08.002
10.3389/fgene.2021.743505
10.1186/s12951-024-02582-6
10.3389/fmolb.2021.629888
10.1038/nrd4140
10.1007/s00018-021-03929-0
10.1016/j.lfs.2021.119399
10.1007/s10565-019-09461-z
10.1038/s41556-024-01361-7
10.1080/10715762.2021.1962009
10.1038/s41420-023-01660-2
10.1016/0092-8674(93)90529-Y
10.1016/0092-8674(93)90530-4
10.1038/nrc706
ContentType Journal Article
Copyright 2024. The Author(s).
COPYRIGHT 2024 BioMed Central Ltd.
The Author(s) 2024 2024
Copyright_xml – notice: 2024. The Author(s).
– notice: COPYRIGHT 2024 BioMed Central Ltd.
– notice: The Author(s) 2024 2024
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOA
DOI 10.1186/s12943-024-02088-7
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList


MEDLINE
CrossRef

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Biology
EISSN 1476-4598
EndPage 22
ExternalDocumentID oai_doaj_org_article_be6e4047b2b4482195e4c75468cfa0c2
PMC11348582
A808376877
39192329
10_1186_s12943_024_02088_7
Genre Journal Article
Review
GrantInformation_xml – fundername: Science Foundation of AMHT
  grantid: 2022YK01
– fundername: Science Foundation of ASCH
  grantid: YN202402; YN202423
GroupedDBID ---
0R~
123
29M
2WC
53G
5VS
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAYXX
ABDBF
ABUWG
ACGFO
ACGFS
ACIHN
ACIWK
ACMJI
ACPRK
ACUHS
ADBBV
ADRAZ
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AFRAH
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
CS3
DIK
DU5
E3Z
EAD
EAP
EAS
EBD
EBLON
EBS
EMB
EMK
EMOBN
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HH5
HMCUK
HYE
IAO
IHR
INH
INR
ITC
KQ8
LGEZI
LOTEE
M1P
M48
M~E
NADUK
NXXTH
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
PZZ
RBZ
RNS
ROL
RPM
RSV
SBL
SOJ
SV3
TR2
TUS
UKHRP
W2D
WOQ
WOW
XSB
-A0
3V.
ACRMQ
ADINQ
C24
CGR
CUY
CVF
ECM
EIF
FRP
NPM
PMFND
7X8
PPXIY
5PM
PJZUB
PUEGO
ID FETCH-LOGICAL-c536t-ce8093241384093b10a2dbacbbd68a1b1170cadb7de48c1d013e107c031dd3
IEDL.DBID M48
ISSN 1476-4598
IngestDate Wed Aug 27 01:31:59 EDT 2025
Thu Aug 21 18:32:13 EDT 2025
Fri Jul 11 02:03:09 EDT 2025
Tue Jun 17 22:04:02 EDT 2025
Tue Jun 10 21:02:38 EDT 2025
Wed Feb 19 02:09:47 EST 2025
Tue Jul 01 01:01:23 EDT 2025
Thu Apr 24 23:11:15 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Non-coding RNAs
Ferroptosis
Drug resistance
Cancer
Language English
License 2024. The Author(s).
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c536t-ce8093241384093b10a2dbacbbd68a1b1170cadb7de48c1d013e107c031dd3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s12943-024-02088-7
PMID 39192329
PQID 3097851785
PQPubID 23479
PageCount 22
ParticipantIDs doaj_primary_oai_doaj_org_article_be6e4047b2b4482195e4c75468cfa0c2
pubmedcentral_primary_oai_pubmedcentral_nih_gov_11348582
proquest_miscellaneous_3097851785
gale_infotracmisc_A808376877
gale_infotracacademiconefile_A808376877
pubmed_primary_39192329
crossref_citationtrail_10_1186_s12943_024_02088_7
crossref_primary_10_1186_s12943_024_02088_7
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2024-08-27
PublicationDateYYYYMMDD 2024-08-27
PublicationDate_xml – month: 08
  year: 2024
  text: 2024-08-27
  day: 27
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle Molecular cancer
PublicationTitleAlternate Mol Cancer
PublicationYear 2024
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References AM Schmitt (2088_CR213) 2016; 29
Y Luo (2088_CR33) 2021; 45
I Poursaitidis (2088_CR89) 2017; 18
S Doll (2088_CR85) 2017; 13
B Han (2088_CR162) 2023; 274
YG Assaraf (2088_CR40) 2019; 46
M Ensoy (2088_CR32) 2023; 30
N Wu (2088_CR200) 2023; 46
D Lenkala (2088_CR211) 2014; 133
L Li (2088_CR185) 2023; 30
T Fojo (2088_CR44) 2003; 22
B Hassannia (2088_CR98) 2019; 35
C Zhang (2088_CR28) 2022; 21
H Song (2088_CR154) 2020; 5
MM Gaschler (2088_CR95) 2018; 13
C Vianello (2088_CR149) 2024; 16
A Balihodzic (2088_CR31) 2022; 29
CJ Brown (2088_CR203) 1992; 71
S Wang (2088_CR199) 2022; 37
FP Freitas (2088_CR125) 2024; 626
H Chen (2088_CR176) 2023; 24
M Entezari (2088_CR144) 2022; 173
JP Friedmann Angeli (2088_CR24) 2019; 19
T Gutschner (2088_CR212) 2012; 9
J Zhu (2088_CR181) 2024; 10
R Brigelius-Flohé (2088_CR110) 2020; 33
JC Chan (2088_CR132) 2020; 45
BR Stockwell (2088_CR80) 2017; 171
GC Forcina (2088_CR106) 2019; 19
R Rupaimoole (2088_CR216) 2017; 16
G Yalcin-Ozkat (2088_CR8) 2021; 59
M Matsui (2088_CR158) 2017; 16
Z Shang (2088_CR193) 2023; 238
SM Elgendy (2088_CR23) 2020; 155
T Nakamura (2088_CR118) 2023; 619
2088_CR2
BR Stockwell (2088_CR16) 2022; 185
L Yin (2088_CR71) 2022; 244
D Hanahan (2088_CR137) 2022; 12
Y Zou (2088_CR88) 2020; 16
2088_CR1
ZJ Law (2088_CR62) 2021; 8
JP Friedmann Angeli (2088_CR107) 2014; 16
J Luo (2088_CR182) 2022; 186
X Liu (2088_CR167) 2024; 10
HP Mohammad (2088_CR138) 2019; 25
F Nappi (2088_CR207) 2024; 25
I Ingold (2088_CR108) 2018; 172
W Jiang (2088_CR152) 2020; 50
J Guo (2088_CR18) 2018; 50
H Sato (2088_CR115) 1999; 274
RT Lima (2088_CR46) 2004; 11
R Alves (2088_CR52) 2019; 9
A Gomaa (2088_CR163) 2019; 9
C Bao (2088_CR169) 2021; 55
2088_CR13
X Liu (2088_CR25) 2022; 13
L Pedrera (2088_CR120) 2021; 28
D Sousa (2088_CR64) 2015; 21
S Maier (2088_CR49) 2005; 5
E Dai (2088_CR119) 2020; 523
QL Liu (2088_CR148) 2021; 78
M Ashrafizadeh (2088_CR143) 2022; 59
C Swanton (2088_CR55) 2012; 72
Q Chen (2088_CR183) 2021; 7
M Conrad (2088_CR84) 2019; 15
R Yang (2088_CR5) 2022; 10
2088_CR175
G Lei (2088_CR15) 2021; 12
GA Calin (2088_CR210) 2006; 66
TM Seibt (2088_CR112) 2019; 133
S Doll (2088_CR117) 2019; 575
SH Deng (2088_CR159) 2021; 549
E Ozkan (2088_CR26) 2022; 29
M Pi (2088_CR68) 2022; 61
ST Taylor (2088_CR50) 2000; 92
G Lei (2088_CR20) 2022; 22
I Dagogo-Jack (2088_CR45) 2018; 15
2088_CR168
2088_CR165
C Xavier (2088_CR60) 2021; 501
L Huo (2088_CR70) 2023; 257
J Helberg (2088_CR83) 2021; 50
Y Ma (2088_CR194) 2023; 16
P Borst (2088_CR43) 2002; 71
PC Zamecnik (2088_CR208) 1978; 75
FL Dong (2088_CR198) 2024; 22
N Wang (2088_CR4) 2023; 8
DB Longley (2088_CR42) 2005; 205
P Ramos (2088_CR11) 2015; 34
X Chen (2088_CR97) 2021; 17
R Brigelius-Flohé (2088_CR111) 2013; 1830
X Jiang (2088_CR76) 2021; 22
X Sun (2088_CR21) 2016; 63
MR Valashedi (2088_CR34) 2022; 35
B Xie (2088_CR36) 2021; 7
R Alves (2088_CR65) 2015; 39
Y Gao (2088_CR186) 2023; 17
P Koppula (2088_CR114) 2018; 38
N Milman (2088_CR63) 2019; 45
K Bersuker (2088_CR116) 2019; 575
C Mao (2088_CR123) 2021; 593
X Li (2088_CR188) 2023; 42
T Haider (2088_CR10) 2020; 72
X Zheng (2088_CR57) 2015; 527
D Kadel (2088_CR59) 2019; 35
Y Ma (2088_CR153) 2024; 15
H Ling (2088_CR215) 2013; 12
SJ Dixon (2088_CR14) 2012; 149
X Li (2088_CR134) 2018; 19
WS Yang (2088_CR109) 2014; 156
F Shu (2088_CR141) 2023; 8
Y Sun (2088_CR105) 2022; 14
Y Wang (2088_CR27) 2023; 66
L Garcia-Martinez (2088_CR139) 2021; 12
R Nussinov (2088_CR12) 2021; 59
2088_CR124
L Wang (2088_CR67) 2021; 8
TS Anthonymuthu (2088_CR93) 2021; 38
LE Pope (2088_CR75) 2023; 33
S Zhen (2088_CR190) 2024; 10
JW Park (2088_CR135) 2019; 42
H Zhang (2088_CR164) 2020; 19
B Wightman (2088_CR205) 1993; 75
Y Gu (2088_CR69) 2023; 247
J Lieberman (2088_CR201) 2018; 25
RT Lima (2088_CR53) 2011; 47
D Wang (2088_CR35) 2022; 13
S Doll (2088_CR82) 2017; 69
ML Stephenson (2088_CR209) 1978; 75
MM Faheem (2088_CR56) 2020; 6
P Sharma (2088_CR61) 2017; 168
SJ Dixon (2088_CR101) 2015; 10
SJ Hogg (2088_CR129) 2020; 19
RC Lee (2088_CR204) 1993; 75
2088_CR87
X Chen (2088_CR99) 2020; 8
2088_CR81
YB Zuo (2088_CR37) 2022; 18
PE Saw (2088_CR146) 2021; 64
E Ozyerli-Goknar (2088_CR51) 2021; 13
X Hua (2088_CR156) 2019; 118
R Qi (2088_CR166) 2023; 68
VE Kagan (2088_CR86) 2017; 13
S David (2088_CR100) 2022; 37
Y Cheng (2088_CR136) 2019; 4
MM Gottesman (2088_CR41) 2002; 2
P Valent (2088_CR54) 2012; 12
L Xiang (2088_CR177) 2021; 66
SW Ryter (2088_CR104) 2007; 9
P Icard (2088_CR66) 2021; 22
W Wang (2088_CR22) 2019; 569
HD Zhang (2088_CR155) 2021; 99
Z Liu (2088_CR197) 2020; 6
Yang (2088_CR94) 2016; 113
Z Xu (2088_CR170) 2021; 55
M Winkle (2088_CR206) 2021; 20
2088_CR96
Y Li (2088_CR126) 2024; 626
L Bu (2088_CR58) 2020; 111
A Chow (2088_CR3) 2022; 19
F Ursini (2088_CR113) 1982; 710
X Lin (2088_CR30) 2021; 75
2088_CR90
W Shanshan (2088_CR191) 2021; 12
B Chu (2088_CR91) 2019; 21
C Ling (2088_CR140) 2019; 29
M Soula (2088_CR122) 2020; 16
N Vasan (2088_CR6) 2019; 575
X Qu (2088_CR178) 2023; 68
X Jiang (2088_CR184) 2022; 12
N Brockdorff (2088_CR202) 1992; 71
K Hadian (2088_CR74) 2020; 181
Z Shi (2088_CR187) 2023; 13
N Schonrock (2088_CR214) 2016; 16
JC Marine (2088_CR38) 2020; 20
J Sun (2088_CR173) 2023; 9
S Mirzaei (2088_CR145) 2022; 15
K Qin (2088_CR192) 2023; 56
X Song (2088_CR195) 2024; 292
H Wang (2088_CR17) 2021; 29
SW Lowe (2088_CR48) 2004; 432
B Gan (2088_CR77) 2021; 220
D Liang (2088_CR79) 2022; 82
2088_CR78
SQ Li (2088_CR180) 2024; 29
2088_CR73
Y Wang (2088_CR131) 2023; 22
Z Song (2088_CR160) 2021; 276
KM Debatin (2088_CR47) 2004; 23
2088_CR72
G Bi (2088_CR161) 2022; 28
R Shah (2088_CR92) 2018; 4
Z Wang (2088_CR171) 2024; 170
Y Wang (2088_CR130) 2023; 8
L Guo (2088_CR172) 2023; 14
Q Zhang (2088_CR217) 2023; 21
AC Gonçalves (2088_CR29) 2021; 59
X Kang (2088_CR179) 2022; 12
C Xu (2088_CR189) 2023; 191
B Chen (2088_CR151) 2022; 7
Y Lu (2088_CR174) 2022; 41
Z Dai (2088_CR133) 2020; 21
KM Hanssen (2088_CR9) 2021; 59
2088_CR103
W Yao (2088_CR196) 2021; 11
2088_CR102
G Lei (2088_CR19) 2020; 30
FH Sarkar (2088_CR157) 2010; 13
SU Khan (2088_CR39) 2024; 22
M Yang (2088_CR142) 2023; 4
V Kraft (2088_CR121) 2020; 6
W Chen (2088_CR147) 2023; 15
J Cao (2088_CR127) 2020; 6
G Cavalli (2088_CR128) 2019; 571
C Xue (2088_CR150) 2022; 13
C Holohan (2088_CR7) 2013; 13
References_xml – volume: 30
  start-page: 146
  issue: 2
  year: 2020
  ident: 2088_CR19
  publication-title: Cell Res
  doi: 10.1038/s41422-019-0263-3
– volume: 13
  start-page: 714
  year: 2013
  ident: 2088_CR7
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc3599
– volume: 75
  start-page: 280
  year: 1978
  ident: 2088_CR208
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.75.1.280
– ident: 2088_CR103
  doi: 10.1016/j.tcb.2023.04.005
– volume: 8
  start-page: 691795
  year: 2021
  ident: 2088_CR67
  publication-title: Front Mol Biosci
  doi: 10.3389/fmolb.2021.691795
– volume: 8
  start-page: 69
  issue: 1
  year: 2023
  ident: 2088_CR4
  publication-title: Signal Transduct Target Ther
  doi: 10.1038/s41392-023-01341-7
– volume: 39
  start-page: 355
  year: 2015
  ident: 2088_CR65
  publication-title: Leuk Res
  doi: 10.1016/j.leukres.2014.12.008
– volume: 626
  start-page: 411
  year: 2024
  ident: 2088_CR126
  publication-title: Nature
  doi: 10.1038/s41586-023-06983-9
– volume: 133
  start-page: 144
  year: 2019
  ident: 2088_CR112
  publication-title: Free Radic Biol Med
  doi: 10.1016/j.freeradbiomed.2018.09.014
– volume: 15
  start-page: 81
  year: 2018
  ident: 2088_CR45
  publication-title: Nat Rev Clin Oncol
  doi: 10.1038/nrclinonc.2017.166
– volume: 172
  start-page: 409
  issue: 3
  year: 2018
  ident: 2088_CR108
  publication-title: Cell
  doi: 10.1016/j.cell.2017.11.048
– volume: 171
  start-page: 273
  issue: 2
  year: 2017
  ident: 2088_CR80
  publication-title: Cell
  doi: 10.1016/j.cell.2017.09.021
– volume: 59
  start-page: 100795
  year: 2021
  ident: 2088_CR9
  publication-title: Drug Resist Updat
  doi: 10.1016/j.drup.2021.100795
– volume: 19
  start-page: 43
  year: 2020
  ident: 2088_CR164
  publication-title: Mol Cancer
  doi: 10.1186/s12943-020-01168-8
– volume: 118
  start-page: 109233
  year: 2019
  ident: 2088_CR156
  publication-title: Biomed Pharmacother
  doi: 10.1016/j.biopha.2019.109233
– volume: 185
  start-page: 2401
  issue: 14
  year: 2022
  ident: 2088_CR16
  publication-title: Cell
  doi: 10.1016/j.cell.2022.06.003
– volume: 13
  start-page: 57
  issue: 3
  year: 2010
  ident: 2088_CR157
  publication-title: Drug Resist Updat
  doi: 10.1016/j.drup.2010.02.001
– ident: 2088_CR87
  doi: 10.1016/j.molcel.2020.11.024
– ident: 2088_CR2
  doi: 10.3390/ijms21093233
– volume: 168
  start-page: 707
  year: 2017
  ident: 2088_CR61
  publication-title: Cell
  doi: 10.1016/j.cell.2017.01.017
– volume: 593
  start-page: 586
  year: 2021
  ident: 2088_CR123
  publication-title: Nature
  doi: 10.1038/s41586-021-03539-7
– volume: 6
  start-page: 72
  year: 2020
  ident: 2088_CR197
  publication-title: Cell Death Discov
  doi: 10.1038/s41420-020-00306-x
– ident: 2088_CR13
  doi: 10.1038/s41556-024-01360-8
– volume: 220
  start-page: e202105043
  year: 2021
  ident: 2088_CR77
  publication-title: J Cell Biol
  doi: 10.1083/jcb.202105043
– volume: 173
  start-page: 103680
  year: 2022
  ident: 2088_CR144
  publication-title: Crit Rev Oncol Hematol
  doi: 10.1016/j.critrevonc.2022.103680
– volume: 274
  start-page: 104777
  year: 2023
  ident: 2088_CR162
  publication-title: J Proteom
  doi: 10.1016/j.jprot.2022.104777
– volume: 19
  start-page: 776
  year: 2020
  ident: 2088_CR129
  publication-title: Nat Rev Drug Discov
  doi: 10.1038/s41573-020-0077-5
– volume: 16
  start-page: 1079
  year: 2023
  ident: 2088_CR194
  publication-title: Pharmacogenomics Personalized Med
  doi: 10.2147/PGPM.S426205
– volume: 13
  start-page: 91
  year: 2017
  ident: 2088_CR85
  publication-title: Nat Chem Biol
  doi: 10.1038/nchembio.2239
– volume: 28
  start-page: 1644
  issue: 5
  year: 2021
  ident: 2088_CR120
  publication-title: Cell Death Differ
  doi: 10.1038/s41418-020-00691-x
– volume: 10
  start-page: 101
  year: 2024
  ident: 2088_CR181
  publication-title: Cell Death Discov
  doi: 10.1038/s41420-024-01866-y
– volume: 38
  start-page: 12
  issue: 1
  year: 2018
  ident: 2088_CR114
  publication-title: Cancer Commun (Lond)
– volume: 45
  start-page: 829
  issue: 10
  year: 2020
  ident: 2088_CR132
  publication-title: Trends Biochem Sci
  doi: 10.1016/j.tibs.2020.05.009
– volume: 111
  start-page: 3468
  year: 2020
  ident: 2088_CR58
  publication-title: Cancer Sci
  doi: 10.1111/cas.14578
– volume: 71
  start-page: 515
  year: 1992
  ident: 2088_CR202
  publication-title: Cell
  doi: 10.1016/0092-8674(92)90519-I
– volume: 17
  start-page: 2054
  issue: 9
  year: 2021
  ident: 2088_CR97
  publication-title: Autophagy
  doi: 10.1080/15548627.2020.1810918
– volume: 29
  start-page: 41
  issue: 1
  year: 2022
  ident: 2088_CR26
  publication-title: Curr Med Chem
  doi: 10.2174/0929867328666210810115812
– volume: 21
  start-page: 579
  year: 2019
  ident: 2088_CR91
  publication-title: Nat Cell Biol
  doi: 10.1038/s41556-019-0305-6
– volume: 15
  start-page: 312
  issue: 5
  year: 2024
  ident: 2088_CR153
  publication-title: Cell Death Dis
  doi: 10.1038/s41419-024-06698-3
– volume: 29
  start-page: 1028
  year: 2019
  ident: 2088_CR140
  publication-title: Cell Metab
  doi: 10.1016/j.cmet.2019.03.009
– volume: 12
  start-page: 836
  year: 2021
  ident: 2088_CR15
  publication-title: Protein Cell
  doi: 10.1007/s13238-021-00841-y
– volume: 59
  start-page: 100789
  year: 2021
  ident: 2088_CR8
  publication-title: Drug Resist Updat
  doi: 10.1016/j.drup.2021.100789
– volume: 523
  start-page: 966
  issue: 4
  year: 2020
  ident: 2088_CR119
  publication-title: Biochem Biophys Res Commun
  doi: 10.1016/j.bbrc.2020.01.066
– volume: 29
  start-page: 835
  year: 2024
  ident: 2088_CR180
  publication-title: Apoptosis
  doi: 10.1007/s10495-024-01948-3
– volume: 92
  start-page: 18
  year: 2000
  ident: 2088_CR50
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/92.1.18
– volume: 37
  start-page: 150
  issue: 1–3
  year: 2022
  ident: 2088_CR100
  publication-title: Antioxid Redox Signal
  doi: 10.1089/ars.2021.0218
– volume: 19
  start-page: 563
  issue: 9
  year: 2018
  ident: 2088_CR134
  publication-title: Nat Rev Mol Cell Biol
  doi: 10.1038/s41580-018-0029-7
– volume: 244
  start-page: 114861
  year: 2022
  ident: 2088_CR71
  publication-title: Eur J Med Chem
  doi: 10.1016/j.ejmech.2022.114861
– volume: 156
  start-page: 317
  issue: 1–2
  year: 2014
  ident: 2088_CR109
  publication-title: Cell
  doi: 10.1016/j.cell.2013.12.010
– volume: 16
  start-page: 1180
  year: 2014
  ident: 2088_CR107
  publication-title: Nat Cell Biol
  doi: 10.1038/ncb3064
– volume: 17
  start-page: 22240
  year: 2023
  ident: 2088_CR186
  publication-title: ACS Nano
  doi: 10.1021/acsnano.3c01199
– volume: 16
  start-page: 167
  issue: 3
  year: 2017
  ident: 2088_CR158
  publication-title: Nat Rev Drug Discov
  doi: 10.1038/nrd.2016.117
– volume: 155
  start-page: 103095
  year: 2020
  ident: 2088_CR23
  publication-title: Crit Rev Oncol Hematol
  doi: 10.1016/j.critrevonc.2020.103095
– volume: 8
  start-page: 32
  year: 2023
  ident: 2088_CR141
  publication-title: Signal Transduct Target Ther
  doi: 10.1038/s41392-022-01300-8
– volume: 25
  start-page: 3630
  year: 2024
  ident: 2088_CR207
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms25073630
– volume: 21
  start-page: 514
  year: 2023
  ident: 2088_CR217
  publication-title: J Transl Med
  doi: 10.1186/s12967-023-04370-6
– volume: 9
  start-page: 9666
  year: 2019
  ident: 2088_CR52
  publication-title: Sci Rep
  doi: 10.1038/s41598-019-46132-9
– volume: 16
  start-page: 203
  year: 2017
  ident: 2088_CR216
  publication-title: Nat Rev Drug Discov
  doi: 10.1038/nrd.2016.246
– volume: 29
  start-page: 1094
  issue: 6
  year: 2022
  ident: 2088_CR31
  publication-title: Cell Death Differ
  doi: 10.1038/s41418-022-00998-x
– volume: 6
  start-page: 51
  year: 2020
  ident: 2088_CR56
  publication-title: Cell Death Discov
  doi: 10.1038/s41420-020-0286-z
– volume: 13
  start-page: e1300
  issue: 6
  year: 2023
  ident: 2088_CR187
  publication-title: Clin Transl Med
  doi: 10.1002/ctm2.1300
– ident: 2088_CR1
  doi: 10.1042/BSR20211812
– volume: 13
  start-page: 544
  issue: 6
  year: 2022
  ident: 2088_CR35
  publication-title: Cell Death Dis
  doi: 10.1038/s41419-022-04927-1
– volume: 19
  start-page: e1800311
  issue: 18
  year: 2019
  ident: 2088_CR106
  publication-title: Proteomics
  doi: 10.1002/pmic.201800311
– volume: 149
  start-page: 1060
  issue: 5
  year: 2012
  ident: 2088_CR14
  publication-title: Cell
  doi: 10.1016/j.cell.2012.03.042
– ident: 2088_CR102
  doi: 10.1155/2014/360438
– volume: 8
  start-page: 449
  issue: 1
  year: 2023
  ident: 2088_CR130
  publication-title: Signal Transduct Target Ther
  doi: 10.1038/s41392-023-01720-0
– volume: 42
  start-page: 159
  issue: 2
  year: 2019
  ident: 2088_CR135
  publication-title: Arch Pharm Res
  doi: 10.1007/s12272-019-01126-z
– ident: 2088_CR124
  doi: 10.1016/j.cell.2023.05.003
– volume: 50
  start-page: 7343
  year: 2021
  ident: 2088_CR83
  publication-title: Chem Soc Rev
  doi: 10.1039/D1CS00265A
– volume: 61
  start-page: 100822
  year: 2022
  ident: 2088_CR68
  publication-title: Drug Resist Updat
  doi: 10.1016/j.drup.2022.100822
– volume: 6
  start-page: 41
  issue: 1
  year: 2020
  ident: 2088_CR121
  publication-title: ACS Cent Sci
  doi: 10.1021/acscentsci.9b01063
– volume: 22
  start-page: 7512
  year: 2003
  ident: 2088_CR44
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1206951
– volume: 7
  start-page: 311
  year: 2021
  ident: 2088_CR183
  publication-title: Cell Death Discov
  doi: 10.1038/s41420-021-00709-4
– volume: 59
  start-page: 100796
  year: 2021
  ident: 2088_CR12
  publication-title: Drug Resist Updat
  doi: 10.1016/j.drup.2021.100796
– volume: 10
  start-page: 1604
  issue: 7
  year: 2015
  ident: 2088_CR101
  publication-title: ACS Chem Biol
  doi: 10.1021/acschembio.5b00245
– volume: 37
  start-page: 1597
  year: 2022
  ident: 2088_CR199
  publication-title: Environ Toxicol
  doi: 10.1002/tox.23509
– volume: 63
  start-page: 173
  issue: 1
  year: 2016
  ident: 2088_CR21
  publication-title: Hepatology
  doi: 10.1002/hep.28251
– volume: 33
  start-page: 1077
  issue: 12
  year: 2023
  ident: 2088_CR75
  publication-title: Trends Cell Biol
  doi: 10.1016/j.tcb.2023.05.003
– volume: 42
  start-page: 960327122114281
  year: 2023
  ident: 2088_CR188
  publication-title: Hum Exp Toxicol
  doi: 10.1177/09603271221142818
– volume: 18
  start-page: 2547
  year: 2017
  ident: 2088_CR89
  publication-title: Cell Rep
  doi: 10.1016/j.celrep.2017.02.054
– volume: 133
  start-page: 931
  year: 2014
  ident: 2088_CR211
  publication-title: Hum Genet
  doi: 10.1007/s00439-014-1434-4
– volume: 72
  start-page: 1125
  issue: 5
  year: 2020
  ident: 2088_CR10
  publication-title: Pharmacol Rep
  doi: 10.1007/s43440-020-00138-7
– volume: 29
  start-page: 2185
  year: 2021
  ident: 2088_CR17
  publication-title: Mol Ther
  doi: 10.1016/j.ymthe.2021.03.022
– volume: 16
  start-page: 302
  year: 2020
  ident: 2088_CR88
  publication-title: Nat Chem Biol
  doi: 10.1038/s41589-020-0472-6
– volume: 7
  start-page: 121
  issue: 1
  year: 2022
  ident: 2088_CR151
  publication-title: Signal Transduct Target Ther
  doi: 10.1038/s41392-022-00975-3
– volume: 30
  start-page: 704
  year: 2023
  ident: 2088_CR185
  publication-title: Cancer Gene Ther
  doi: 10.1038/s41417-022-00581-z
– ident: 2088_CR78
  doi: 10.1016/j.molcel.2018.10.042
– volume: 99
  start-page: 84
  issue: 1
  year: 2021
  ident: 2088_CR155
  publication-title: Clin Genet
  doi: 10.1111/cge.13800
– volume: 575
  start-page: 299
  issue: 7782
  year: 2019
  ident: 2088_CR6
  publication-title: Nature
  doi: 10.1038/s41586-019-1730-1
– volume: 45
  start-page: 29
  issue: 1
  year: 2021
  ident: 2088_CR33
  publication-title: Oncol Rep
  doi: 10.3892/or.2020.7836
– volume: 113
  start-page: E4966
  issue: 34
  year: 2016
  ident: 2088_CR94
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.1603244113
– ident: 2088_CR175
  doi: 10.1136/jitc-2021-004381
– volume: 19
  start-page: 775
  issue: 12
  year: 2022
  ident: 2088_CR3
  publication-title: Nat Rev Clin Oncol
  doi: 10.1038/s41571-022-00689-z
– volume: 46
  start-page: 1573
  year: 2023
  ident: 2088_CR200
  publication-title: J Endocrinol Invest
  doi: 10.1007/s40618-023-02010-w
– volume: 66
  start-page: 7390
  year: 2006
  ident: 2088_CR210
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-06-0800
– volume: 4
  start-page: 387
  issue: 3
  year: 2018
  ident: 2088_CR92
  publication-title: ACS Cent Sci
  doi: 10.1021/acscentsci.7b00589
– volume: 274
  start-page: 11455
  issue: 17
  year: 1999
  ident: 2088_CR115
  publication-title: J Biol Chem
  doi: 10.1074/jbc.274.17.11455
– volume: 16
  start-page: 1351
  issue: 12
  year: 2020
  ident: 2088_CR122
  publication-title: Nat Chem Biol
  doi: 10.1038/s41589-020-0613-y
– volume: 575
  start-page: 688
  issue: 7784
  year: 2019
  ident: 2088_CR116
  publication-title: Nature
  doi: 10.1038/s41586-019-1705-2
– volume: 66
  start-page: 100916
  year: 2023
  ident: 2088_CR27
  publication-title: Updat
– volume: 15
  start-page: 18
  issue: 1
  year: 2022
  ident: 2088_CR145
  publication-title: J Hematol Oncol
  doi: 10.1186/s13045-022-01235-1
– volume: 9
  start-page: 703
  year: 2012
  ident: 2088_CR212
  publication-title: RNA Biol
  doi: 10.4161/rna.20481
– volume: 25
  start-page: 357
  year: 2018
  ident: 2088_CR201
  publication-title: Nat Struct Mol Biol
  doi: 10.1038/s41594-018-0054-4
– volume: 181
  start-page: 1188
  issue: 5
  year: 2020
  ident: 2088_CR74
  publication-title: Ferroptosis Cell
  doi: 10.1016/j.cell.2020.04.039
– volume: 186
  start-page: 27
  year: 2022
  ident: 2088_CR182
  publication-title: Brain Res Bull
  doi: 10.1016/j.brainresbull.2022.04.005
– volume: 47
  start-page: 163
  year: 2011
  ident: 2088_CR53
  publication-title: Eur J Cancer
  doi: 10.1016/j.ejca.2010.11.005
– volume: 22
  start-page: 102
  issue: 1
  year: 2023
  ident: 2088_CR131
  publication-title: Mol Cancer
  doi: 10.1186/s12943-023-01810-1
– volume: 12
  start-page: 1786
  year: 2021
  ident: 2088_CR139
  publication-title: Nat Commun
  doi: 10.1038/s41467-021-22024-3
– volume: 50
  start-page: 445
  issue: 2
  year: 2018
  ident: 2088_CR18
  publication-title: Cancer Res Treat
  doi: 10.4143/crt.2016.572
– volume: 4
  start-page: 62
  year: 2019
  ident: 2088_CR136
  publication-title: Signal Transduct Target Ther
  doi: 10.1038/s41392-019-0095-0
– volume: 41
  start-page: 3
  issue: 1
  year: 2022
  ident: 2088_CR174
  publication-title: J Exp Clin Cancer Res
  doi: 10.1186/s13046-021-02208-x
– volume: 22
  start-page: 6587
  year: 2021
  ident: 2088_CR66
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms22126587
– volume: 66
  start-page: 1773
  year: 2021
  ident: 2088_CR177
  publication-title: Sci Bull (Beijing)
  doi: 10.1016/j.scib.2021.01.027
– volume: 21
  start-page: 47
  issue: 1
  year: 2022
  ident: 2088_CR28
  publication-title: Mol Cancer
  doi: 10.1186/s12943-022-01530-y
– volume: 45
  start-page: 1
  year: 2019
  ident: 2088_CR63
  publication-title: Drug Resist Updat
  doi: 10.1016/j.drup.2019.07.003
– volume: 21
  start-page: 737
  issue: 12
  year: 2020
  ident: 2088_CR133
  publication-title: Nat Rev Genet
  doi: 10.1038/s41576-020-0270-8
– volume: 5
  start-page: 223
  year: 2005
  ident: 2088_CR49
  publication-title: Am J Pharmacogenomics
  doi: 10.2165/00129785-200505040-00003
– volume: 13
  start-page: 81
  issue: 1
  year: 2017
  ident: 2088_CR86
  publication-title: Nat Chem Biol
  doi: 10.1038/nchembio.2238
– volume: 619
  start-page: 371
  year: 2023
  ident: 2088_CR118
  publication-title: Nature
  doi: 10.1038/s41586-023-06255-6
– volume: 14
  start-page: 1207496
  year: 2023
  ident: 2088_CR172
  publication-title: Front Pharmacol
  doi: 10.3389/fphar.2023.1207496
– volume: 7
  start-page: 101
  issue: 1
  year: 2021
  ident: 2088_CR36
  publication-title: Cell Death Discov
  doi: 10.1038/s41420-021-00483-3
– volume: 12
  start-page: 939605
  year: 2022
  ident: 2088_CR179
  publication-title: Front Oncol
  doi: 10.3389/fonc.2022.939605
– volume: 23
  start-page: 2950
  year: 2004
  ident: 2088_CR47
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1207558
– volume: 35
  start-page: 830
  issue: 6
  year: 2019
  ident: 2088_CR98
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2019.04.002
– volume: 16
  start-page: 766
  issue: 4
  year: 2024
  ident: 2088_CR149
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers16040766
– volume: 527
  start-page: 525
  year: 2015
  ident: 2088_CR57
  publication-title: Nature
  doi: 10.1038/nature16064
– volume: 33
  start-page: 498
  issue: 7
  year: 2020
  ident: 2088_CR110
  publication-title: Antioxid Redox Signal
  doi: 10.1089/ars.2019.7905
– volume: 257
  start-page: 115438
  year: 2023
  ident: 2088_CR70
  publication-title: Eur J Med Chem
  doi: 10.1016/j.ejmech.2023.115438
– volume: 24
  start-page: 2223377
  issue: 1
  year: 2023
  ident: 2088_CR176
  publication-title: Cancer Biol Ther
  doi: 10.1080/15384047.2023.2223377
– volume: 191
  start-page: 106739
  year: 2023
  ident: 2088_CR189
  publication-title: Pharmacol Res
  doi: 10.1016/j.phrs.2023.106739
– volume: 50
  start-page: 100683
  year: 2020
  ident: 2088_CR152
  publication-title: Drug Resist Updat
  doi: 10.1016/j.drup.2020.100683
– volume: 205
  start-page: 275
  year: 2005
  ident: 2088_CR42
  publication-title: J Pathol
  doi: 10.1002/path.1706
– volume: 72
  start-page: 4875
  year: 2012
  ident: 2088_CR55
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-12-2217
– volume: 29
  start-page: 452
  year: 2016
  ident: 2088_CR213
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2016.03.010
– volume: 9
  start-page: 49
  issue: 1
  year: 2007
  ident: 2088_CR104
  publication-title: Antioxid Redox Signal
  doi: 10.1089/ars.2007.9.49
– volume: 75
  start-page: 285
  year: 1978
  ident: 2088_CR209
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.75.1.285
– volume: 13
  start-page: 3210
  year: 2021
  ident: 2088_CR51
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers13133210
– volume: 75
  start-page: 116
  year: 2021
  ident: 2088_CR30
  publication-title: Semin Cancer Biol
  doi: 10.1016/j.semcancer.2020.12.019
– volume: 4
  start-page: e267
  issue: 3
  year: 2023
  ident: 2088_CR142
  publication-title: MedComm
  doi: 10.1002/mco2.267
– ident: 2088_CR72
  doi: 10.1038/s41580-024-00703-5
– volume: 69
  start-page: 423
  issue: 6
  year: 2017
  ident: 2088_CR82
  publication-title: IUBMB Life
  doi: 10.1002/iub.1616
– volume: 710
  start-page: 197
  year: 1982
  ident: 2088_CR113
  publication-title: Biochim Biophys Acta
  doi: 10.1016/0005-2760(82)90150-3
– volume: 238
  start-page: 2407
  issue: 10
  year: 2023
  ident: 2088_CR193
  publication-title: J Cell Physiol
  doi: 10.1002/jcp.31093
– volume: 170
  start-page: 116074
  year: 2024
  ident: 2088_CR171
  publication-title: Biomed Pharmacother
  doi: 10.1016/j.biopha.2023.116074
– volume: 15
  start-page: 1137
  year: 2019
  ident: 2088_CR84
  publication-title: Nat Chem Biol
  doi: 10.1038/s41589-019-0408-1
– volume: 14
  start-page: 904152
  year: 2022
  ident: 2088_CR105
  publication-title: Front Aging Neurosci
  doi: 10.3389/fnagi.2022.904152
– volume: 68
  start-page: 100936
  year: 2023
  ident: 2088_CR178
  publication-title: Drug Resist Updat
  doi: 10.1016/j.drup.2023.100936
– volume: 35
  start-page: 972
  issue: 4
  year: 2022
  ident: 2088_CR34
  publication-title: Hum Cell
  doi: 10.1007/s13577-022-00699-0
– volume: 292
  start-page: 105055
  year: 2024
  ident: 2088_CR195
  publication-title: J Proteom
  doi: 10.1016/j.jprot.2023.105055
– volume: 569
  start-page: 270
  issue: 7755
  year: 2019
  ident: 2088_CR22
  publication-title: Nature
  doi: 10.1038/s41586-019-1170-y
– volume: 25
  start-page: 403
  issue: 3
  year: 2019
  ident: 2088_CR138
  publication-title: Nat Med
  doi: 10.1038/s41591-019-0376-8
– volume: 82
  start-page: 2215
  issue: 12
  year: 2022
  ident: 2088_CR79
  publication-title: Mol Cell
  doi: 10.1016/j.molcel.2022.03.022
– volume: 30
  start-page: 1638
  issue: 14
  year: 2023
  ident: 2088_CR32
  publication-title: Curr Med Chem
  doi: 10.2174/0929867329666220629154418
– volume: 38
  start-page: 101744
  year: 2021
  ident: 2088_CR93
  publication-title: Redox Biol
  doi: 10.1016/j.redox.2020.101744
– volume: 16
  start-page: 220
  year: 2016
  ident: 2088_CR214
  publication-title: Curr Gene Ther
  doi: 10.2174/1566523216666160524144159
– volume: 22
  start-page: 381
  issue: 7
  year: 2022
  ident: 2088_CR20
  publication-title: Nat Rev Cancer
  doi: 10.1038/s41568-022-00459-0
– volume: 59
  start-page: 100797
  year: 2021
  ident: 2088_CR29
  publication-title: Drug Resist Updat
  doi: 10.1016/j.drup.2021.100797
– volume: 13
  start-page: 847728
  year: 2022
  ident: 2088_CR150
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2022.847728
– volume: 9
  start-page: 16970
  issue: 1
  year: 2019
  ident: 2088_CR163
  publication-title: Sci Rep
  doi: 10.1038/s41598-019-53174-6
– volume: 46
  start-page: 100645
  year: 2019
  ident: 2088_CR40
  publication-title: Drug Resist Updat
  doi: 10.1016/j.drup.2019.100645
– volume: 20
  start-page: 629
  year: 2021
  ident: 2088_CR206
  publication-title: Nat Rev Drug Discov
  doi: 10.1038/s41573-021-00219-z
– volume: 10
  start-page: 875318
  year: 2022
  ident: 2088_CR5
  publication-title: Front Cell Dev Biol
  doi: 10.3389/fcell.2022.875318
– volume: 13
  start-page: 909821
  year: 2022
  ident: 2088_CR25
  publication-title: Front Pharmacol
  doi: 10.3389/fphar.2022.909821
– volume: 22
  start-page: 109
  issue: 1
  year: 2024
  ident: 2088_CR39
  publication-title: Cell Communication Signal
  doi: 10.1186/s12964-023-01302-1
– volume: 71
  start-page: 537
  year: 2002
  ident: 2088_CR43
  publication-title: Annu Rev Biochem
  doi: 10.1146/annurev.biochem.71.102301.093055
– volume: 15
  start-page: 4187
  issue: 16
  year: 2023
  ident: 2088_CR147
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers15164187
– volume: 34
  start-page: 3617
  issue: 28
  year: 2015
  ident: 2088_CR11
  publication-title: Oncogene
  doi: 10.1038/onc.2014.314
– volume: 18
  start-page: 1829
  issue: 5
  year: 2022
  ident: 2088_CR37
  publication-title: Int J Biol Sci
  doi: 10.7150/ijbs.66917
– volume: 19
  start-page: 405
  issue: 7
  year: 2019
  ident: 2088_CR24
  publication-title: Nat Rev Cancer
  doi: 10.1038/s41568-019-0149-1
– volume: 432
  start-page: 307
  year: 2004
  ident: 2088_CR48
  publication-title: Nature
  doi: 10.1038/nature03098
– volume: 247
  start-page: 115015
  year: 2023
  ident: 2088_CR69
  publication-title: Eur J Med Chem
  doi: 10.1016/j.ejmech.2022.115015
– volume: 626
  start-page: 401
  year: 2024
  ident: 2088_CR125
  publication-title: Nature
  doi: 10.1038/s41586-023-06878-9
– ident: 2088_CR165
  doi: 10.1038/s41388-024-03057-6
– ident: 2088_CR73
  doi: 10.1084/jem.20210518
– volume: 59
  start-page: 101606
  year: 2022
  ident: 2088_CR143
  publication-title: Semin Immunol
  doi: 10.1016/j.smim.2022.101606
– ident: 2088_CR90
  doi: 10.1016/j.celrep.2019.07.107
– volume: 5
  start-page: 193
  issue: 1
  year: 2020
  ident: 2088_CR154
  publication-title: Signal Transduct Target Ther
  doi: 10.1038/s41392-020-00300-w
– volume: 12
  start-page: 767
  year: 2012
  ident: 2088_CR54
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc3368
– ident: 2088_CR96
– volume: 6
  start-page: 580
  issue: 7
  year: 2020
  ident: 2088_CR127
  publication-title: Trends Cancer
  doi: 10.1016/j.trecan.2020.02.003
– volume: 71
  start-page: 527
  year: 1992
  ident: 2088_CR203
  publication-title: Cell
  doi: 10.1016/0092-8674(92)90520-M
– volume: 20
  start-page: 743
  issue: 12
  year: 2020
  ident: 2088_CR38
  publication-title: Nat Rev Cancer
  doi: 10.1038/s41568-020-00302-4
– volume: 55
  start-page: 1119
  issue: 11–12
  year: 2021
  ident: 2088_CR170
  publication-title: Free Radic Res
  doi: 10.1080/10715762.2021.2024816
– volume: 501
  start-page: 210
  year: 2021
  ident: 2088_CR60
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2020.11.013
– volume: 10
  start-page: 131
  year: 2024
  ident: 2088_CR190
  publication-title: Cell Death Discov
  doi: 10.1038/s41420-024-01892-w
– volume: 64
  start-page: 22
  issue: 1
  year: 2021
  ident: 2088_CR146
  publication-title: Sci China Life Sci
  doi: 10.1007/s11427-020-1700-9
– volume: 11
  start-page: 309
  year: 2004
  ident: 2088_CR46
  publication-title: Cancer Gene Ther
  doi: 10.1038/sj.cgt.7700706
– volume: 575
  start-page: 693
  issue: 7784
  year: 2019
  ident: 2088_CR117
  publication-title: Nature
  doi: 10.1038/s41586-019-1707-0
– volume: 1830
  start-page: 3289
  issue: 5
  year: 2013
  ident: 2088_CR111
  publication-title: Biochim Biophys Acta
  doi: 10.1016/j.bbagen.2012.11.020
– volume: 11
  start-page: 780938
  year: 2021
  ident: 2088_CR196
  publication-title: Front Oncol
  doi: 10.3389/fonc.2021.780938
– volume: 12
  start-page: 31
  issue: 1
  year: 2022
  ident: 2088_CR137
  publication-title: Cancer Discov
  doi: 10.1158/2159-8290.CD-21-1059
– volume: 549
  start-page: 54
  year: 2021
  ident: 2088_CR159
  publication-title: Biochem Biophys Res Commun
  doi: 10.1016/j.bbrc.2021.02.077
– volume: 56
  start-page: 184
  issue: 2
  year: 2023
  ident: 2088_CR192
  publication-title: BMB Rep
– volume: 13
  start-page: 1013
  year: 2018
  ident: 2088_CR95
  publication-title: ACS Chem Biol
  doi: 10.1021/acschembio.8b00199
– volume: 68
  start-page: 100960
  year: 2023
  ident: 2088_CR166
  publication-title: Drug Resist Updat
  doi: 10.1016/j.drup.2023.100960
– volume: 571
  start-page: 489
  issue: 7766
  year: 2019
  ident: 2088_CR128
  publication-title: Nature
  doi: 10.1038/s41586-019-1411-0
– volume: 28
  start-page: 366
  year: 2022
  ident: 2088_CR161
  publication-title: Mol Ther Nucleic Acids
  doi: 10.1016/j.omtn.2022.03.020
– volume: 10
  start-page: 262
  year: 2024
  ident: 2088_CR167
  publication-title: Cell Death Discov
  doi: 10.1038/s41420-024-02035-x
– volume: 8
  start-page: 590226
  year: 2020
  ident: 2088_CR99
  publication-title: Front Cell Dev Biol
  doi: 10.3389/fcell.2020.590226
– volume: 12
  start-page: 862015
  year: 2022
  ident: 2088_CR184
  publication-title: Front Oncol
  doi: 10.3389/fonc.2022.862015
– volume: 22
  start-page: 266
  year: 2021
  ident: 2088_CR76
  publication-title: Nat Rev Mol Cell Biol
  doi: 10.1038/s41580-020-00324-8
– ident: 2088_CR168
  doi: 10.1155/2022/2843990
– volume: 21
  start-page: 595
  year: 2015
  ident: 2088_CR64
  publication-title: Trends Mol Med
  doi: 10.1016/j.molmed.2015.08.002
– volume: 12
  start-page: 743505
  year: 2021
  ident: 2088_CR191
  publication-title: Front Genet
  doi: 10.3389/fgene.2021.743505
– volume: 22
  start-page: 298
  year: 2024
  ident: 2088_CR198
  publication-title: J Nanobiotechnol
  doi: 10.1186/s12951-024-02582-6
– volume: 8
  start-page: 629888
  year: 2021
  ident: 2088_CR62
  publication-title: Front Mol Biosci
  doi: 10.3389/fmolb.2021.629888
– volume: 12
  start-page: 847
  year: 2013
  ident: 2088_CR215
  publication-title: Nat Rev Drug Discov
  doi: 10.1038/nrd4140
– volume: 78
  start-page: 6823
  issue: 21–22
  year: 2021
  ident: 2088_CR148
  publication-title: Cell Mol Life Sci
  doi: 10.1007/s00018-021-03929-0
– volume: 276
  start-page: 119399
  year: 2021
  ident: 2088_CR160
  publication-title: Life Sci
  doi: 10.1016/j.lfs.2021.119399
– volume: 35
  start-page: 407
  year: 2019
  ident: 2088_CR59
  publication-title: Cell Biol Toxicol
  doi: 10.1007/s10565-019-09461-z
– ident: 2088_CR81
  doi: 10.1038/s41556-024-01361-7
– volume: 55
  start-page: 853
  issue: 7
  year: 2021
  ident: 2088_CR169
  publication-title: Free Radic Res
  doi: 10.1080/10715762.2021.1962009
– volume: 9
  start-page: 362
  issue: 1
  year: 2023
  ident: 2088_CR173
  publication-title: Cell Death Discov
  doi: 10.1038/s41420-023-01660-2
– volume: 75
  start-page: 843
  year: 1993
  ident: 2088_CR204
  publication-title: Cell
  doi: 10.1016/0092-8674(93)90529-Y
– volume: 75
  start-page: 855
  year: 1993
  ident: 2088_CR205
  publication-title: Cell
  doi: 10.1016/0092-8674(93)90530-4
– volume: 2
  start-page: 48
  year: 2002
  ident: 2088_CR41
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc706
SSID ssj0017874
Score 2.517159
SecondaryResourceType review_article
Snippet The development of drug resistance remains a major challenge in cancer treatment. Ferroptosis, a unique type of regulated cell death, plays a pivotal role in...
Abstract The development of drug resistance remains a major challenge in cancer treatment. Ferroptosis, a unique type of regulated cell death, plays a pivotal...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 177
SubjectTerms Animals
Antineoplastic Agents - pharmacology
Antineoplastic Agents - therapeutic use
Cancer
Cell death
Chemotherapy
Development and progression
Drug resistance
Drug Resistance, Neoplasm - genetics
Drug therapy
Epigenesis, Genetic
Epigenetic inheritance
Ferroptosis
Ferroptosis - drug effects
Ferroptosis - genetics
Gene Expression Regulation, Neoplastic - drug effects
Humans
Neoplasms - drug therapy
Neoplasms - genetics
Neoplasms - metabolism
Neoplasms - pathology
Non-coding RNAs
Review
RNA, Untranslated - genetics
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LixQxEA6yoHgRXV-tq0QQPEjYfiTp9HGUXRZh97Aq7C10KokOuNND98xh_71V6Z5hGkEvXvOgk8pXqapOPRh7r32lfAxBuNA0QnoZhSmhEEH6yrkCWpnKvV1e6Yvv8suNujko9UU-YWN64JFwpy7oIHNZu9KhJYH8pYKEWkltILY5pNsXZd7OmJreDxCGchciY_TpgFJN0nulFFSU0oh6JoZStv4_7-QDoTR3mDyQQOeP2aNJdeSLcclP2L2wOmb3x2KSd8fsweX0TP6UfT1bU5JNik_kt50nb6B0ALyLPIa-79abblgO3N1xtP4FdCTA-PXVYuDLFQcCQs99v_3B0RgnBRMbnrHr87Nvny_EVD1BgKr0RkAwOSpnKKTIhqtckbeldy0457VpC0clZ6D1rvZBGig8_Q9FWxCQy72vnrMjXEB4ybjWOCnqBgpXS60a1HNzhQcLLsQyRshYsaOkhSmvOJW3-GWTfWG0Halvkfo2Ud_WGfu4n7Mes2r8dfQnOqD9SMqInRoQJ3bCif0XTjL2gY7XEt_i8qCdwg9wk5QByy4MKqNoe9X4uZPZSOQ3mHW_2wHEUhc5qa1Ctx1sRTExCrGnMvZiBMx-zVVDqnTZZMzMoDTb1LxntfyZ0n0XRSWNMuWr_0GG1-xhmdgA78f6hB1t-m14g2rVxr1NHPQb-pMelg
  priority: 102
  providerName: Directory of Open Access Journals
Title Epigenetic modification of ferroptosis by non-coding RNAs in cancer drug resistance
URI https://www.ncbi.nlm.nih.gov/pubmed/39192329
https://www.proquest.com/docview/3097851785
https://pubmed.ncbi.nlm.nih.gov/PMC11348582
https://doaj.org/article/be6e4047b2b4482195e4c75468cfa0c2
Volume 23
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Zj9MwELb2EIgXBMtVWCojIfGADDkc23lAqIu6WiG1QoWV-mbFR5ZKS1KSVqL_nhk3LRux2lcfiTP-xjMT2_MR8la4NHOl98z4PGfc8ZKpxMbMc5caE9uCB7q3yVRcXPKv82x-QHZ0R50A21tDO-STumyuP_z5vfkMCv8pKLwSH1uwWRx3IzlDyknF5CE5BsskkdFgwv_tKgA4wy4zl4LxLFe7SzS3PqNnqEI-__9X7Rtmq3-k8oaNOn9EHnbOJR1t0fCYHPjqhNzb0k1uTsj9SbeR_oR8Hy8xDSfeYKS_aofnhcIU0bqkpW-aermq20VLzYZWdcVsjSaOzqajli4qahEqDXXN-opCuI4uKBQ8JbPz8Y8vF6zjV2A2S8WKWa8icN_AjGGUl5o4KhJnCmuME6qIDZLS2MIZ6TxXNnb4xxSiRQvrgHPpM3IEA_AvCBUCOpUit7GRXIBcYxNlMPXW-DIpSzsg8U6S2naZx5EA41qHCEQJvZW-BunrIH0tB-T9vs9ym3fjztZnOEH7lpgzOxTUzZXuVFAbLzyPuDSJgZgUVurMcyszLpQti8gmA_IOp1cj1mB4tuguKMBHYo4sPVLgrkJ0JuF1p72WoJG2V_1mBxCNVXiMrfL1utUp3prJAIfZgDzfAmY_5jRHZzvJB0T1oNT7qH5NtfgZEoLHccpVppKXd4_rFXmQBIDD2ihPydGqWfvX4FKtzJAcyrkckuOz8fTbbBh-TAyD7vwFQhwetQ
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Epigenetic+modification+of+ferroptosis+by+non-coding+RNAs+in+cancer+drug+resistance&rft.jtitle=Molecular+cancer&rft.au=Wang%2C+Hongquan&rft.au=Fleishman%2C+Joshua+S&rft.au=Cheng%2C+Sihang&rft.au=Wang%2C+Weixue&rft.date=2024-08-27&rft.pub=BioMed+Central+Ltd&rft.issn=1476-4598&rft.eissn=1476-4598&rft.volume=23&rft.issue=1&rft_id=info:doi/10.1186%2Fs12943-024-02088-7&rft.externalDocID=A808376877
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1476-4598&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1476-4598&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1476-4598&client=summon